BMS renews distribution contract with Yusen Logistics
For the pan-European distribution of OTC and prescription drugs
The two companies have been working together since 2007 when Yusen was appointed to create a lean supply chain for BMS.
BMS co-loads product from multiple plants, as well as with other pharmaceutical firms using Yusen’s European pharmaceutical distribution network, which is known as its ‘superhighway’.
The Yusen operation involves temperature-controlled distribution of more than 120,000 pallets of product per annum from BMS' six manufacturing plants in France, Italy and Ireland. It also collects from third party manufacturers elsewhere in Europe and delivers to more than 80 points in 35 countries throughout Europe.
Eric Plouffe, EMEA associate director, Transportation, Compliance & Logistics Planning at BMS, said: ‘The superhighway provides a temperature-controlled, quality-approved secure solution which meets the ever-increasing regulatory requirements demanded by European Health Agencies. Extending our partnership will enable us to continue to derive benefits within our supply chain while also enjoying additional cost savings.’
All Yusen vehicles used for the service are temperature controlled and have GPS tracking. Additional controls are in place for narcotics to ensure safe delivery.
Looking to the future, Yusen and BMS will continue to work together to create further efficiencies through Yusen's high security network.
You may also like
Trending Articles
You may also like
Media
BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants
Following the Bristol-Myers Squibb (BMS) announcement on 3 January 2019 that it will acquire Celgene in a cash and stock deal with an equity value of approximately $74 billion, Edit Kovalcsik, Managing Pharma Analyst at GlobalData, offers her view on this significant merger
Research & Development
Eisai, BMS and H3 Biomedicine announce research collaboration
Bristol-Myers Squibb, Eisai and its US-based precision medicine research and development subsidiary H3 Biomedicine, have announced a multiyear research collaboration focused on evaluating whether novel therapeutics leveraging H3's RNA splicing platform can provide a more powerful response against cancer
Research & Development
BMS and Vedanta announce a new clinical collaboration to evaluate OPDIVO (nivolumab) and VE800
Bristol-Myers Squibb and Vedanta announce a clinical trial collaboration to evaluate BMS' programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) in combination with Vedanta’s VE800, a rationally defined human bacterial consortium, in patients with advanced or metastatic cancers